Do you want to skip to content? Skip to content
Contact Us Convatec Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本
Convatec Convatec False /oidc-signin/en-us/

Most visited pages

Reports, results and presentations
Contact Us Convatec Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本

06 August 2020

Download Full Press Release

PDF Download

 

Solid H1 performance, strategy implementation on track, COVID-19 challenges continue

Key points:

  • Group reported revenue of $908 million up 2.1% year on year, 4.3% in constant currency1 driven by Continence and Critical Care and Infusion Care, partially offset by lower Advanced Wound Care revenue.
    • As expected, second quarter growth was impacted by lower volumes in Advanced Wound Care and by the unwinding of increased customers’ inventories in Ostomy Care.
  • The strategic transformation is progressing well; with investments proactively re-phased in response to conditions resulting from COVID-19.
    • Recurring transformation investment in 2020 expected to be between $50 million and $55 million (previously $60 million and $65 million), of which $16 million in the first half.
    • As a result, annual gross benefits in 2021 now expected to be between $130 million and $150 million (previously between $150 million and $170 million).
  • Reported EBIT4 of $113 million, 20.7% higher year on year, and Adjusted EBIT2 of $182 million, 10.0% higher, reflecting the prior year rebate provision, temporary cost reductions due to COVID-19 and net productivity gains. Adjusted2 EBIT margin increased to 20.0% (2019: 18.6%).
  • Interim dividend of 1.717 cents declared, in line with the prior year.
  • Reduction in leverage to 2.2x net debt/adjusted EBITDA2, 3 (31 December 2019: 2.5x), adjusted cash conversion2 of 73% (30 June 2019: 90%) with the prior year benefiting from favourable inventory movements.
  • FY2020 outlook maintained: uncertainty and risk of disruption due to COVID-19 remains.
    • Lower revenue growth and higher transformation investment expected in the second half, alongside a return to higher operating expense levels.
a screenshot of a computer

 

Karim Bitar, Chief Executive Officer, commented:

“In the first half, despite the disruption caused by COVID-19, we delivered a solid trading performance and continued to implement our strategy to Pivot to Sustainable and Profitable Growth.

Whilst there remains much work to do, we continue to push forward with key initiatives. In light of the current circumstances, we have accelerated some investments, in particular in our digital capabilities to respond to changes in customer engagement preferences, and our new operating model is embedding well. Conversely, other investments, such as salesforce expansions, have been deferred.

Looking ahead, we remain committed to supporting and protecting our colleagues and the people and care givers we serve, whilst continuing to maintain the resilience of our supply chain. We are conscious of COVID-19 related challenges in the second half, have taken proactive steps to address them where possible and are maintaining our full year outlook.”

(...)

Download the full text of this announcement

PDF Download

 

Enquiries

Analysts and Investors

ir@convatec.com

Mark Reynolds, Director Investor Relations    

+44 (0)7551 036 625

   

Media

mediarelations@convatec.com

Buchanan: Charles Ryland / Chris Lane / Vicky Hayns      

+44 (0)207 466 5000

 

Press Release

See all

5/13/2022

Convatec announces the release of ConvaMax™

Read more

5/13/2022

Interim Results for the 6 months ended 30 June 2020

Read more

5/13/2022

Trading update for the three months ended 30 September 2020

Read more

5/13/2022

Expert panel publishes Wound Hygiene consensus

Read more

5/13/2022

Non-Executive Director appointment

Read more

5/13/2022

Convatec Group Plc Annual Results 2019

Read more

5/13/2022

Trading update for the three months ended 31 March 2020

Read more

5/13/2022

Non-Executive Director appointment

Read more

5/13/2022

Board Changes

Read more

5/13/2022

Non-Executive Director appointment

Read more